Apimeds Pharmaceuticals Us, INC. 8-K Filing
Ticker: APUS · Form: 8-K · Filed: Nov 18, 2025 · CIK: 1894525
| Field | Detail |
|---|---|
| Company | Apimeds Pharmaceuticals Us, INC. (APUS) |
| Form Type | 8-K |
| Filed Date | Nov 18, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01, $500,000 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Apimeds Pharmaceuticals Us, INC. (ticker: APUS) to the SEC on Nov 18, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.01 (ch registered Common Stock, par value $0.01 per share APUS NYSE American LLC); $500,000 (s the Executive's annual base salary to $500,000. It also provides that, if the Executiv).
How long is this filing?
Apimeds Pharmaceuticals Us, INC.'s 8-K filing is 2 pages with approximately 595 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 595 words · 2 min read · ~2 pages · Grade level 13 · Accepted 2025-11-18 16:57:40
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share APUS NYSE American LLC
- $500,000 — s the Executive's annual base salary to $500,000. It also provides that, if the Executiv
Filing Documents
- ea0266166-8k_apimeds.htm (8-K) — 24KB
- ea026616601ex10-1_apimeds.htm (EX-10.1) — 10KB
- 0001213900-25-112184.txt ( ) — 199KB
- apus-20251113.xsd (EX-101.SCH) — 3KB
- apus-20251113_lab.xml (EX-101.LAB) — 33KB
- apus-20251113_pre.xml (EX-101.PRE) — 22KB
- ea0266166-8k_apimeds_htm.xml (XML) — 4KB
02. Departure of Directors or Certain Officers; Election
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 13, 2025 (the "Effective Date"), Apimeds Pharmaceuticals US, Inc. (the "Company") entered into an amendment (the "Amendment") to the Executive Employment Agreement, dated September 21, 2023 (the "Agreement"), with Erik Emerson, the Company's Chief Executive Officer (the "Executive"). Effective as of the Effective Date, the Amendment increases the Executive's annual base salary to $500,000. It also provides that, if the Executive is terminated by the Company without cause, the Executive will be entitled to a severance payment equal to twenty-four (24) months of base salary and benefits and immediate vesting of all unvested equity, subject to the Executive's execution of a release of claims against the Company. The amendment further clarifies that, upon termination by the Company for cause or by the Executive without good reason, any unvested equity will be automatically forfeited without payment or consideration by the Company. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Amendment to Executive Employment Agreement, dated November 13, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Apimeds Pharmaceuticals US, Inc. Date: November 18, 2025 By: /s/ Erik Emerson Name: Erik Emerson Title: Chief Executive Officer 2